Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regeneron

Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers

The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and more.

Regeneron Culls Losses After High-Dose Eylea Sales Disappoint

Regeneron Culls Losses After High-Dose Eylea Sales Disappoint

Regeneron stock recovered Monday after the drugmaker preannounced light sales of a high-dose version of eye drug Eylea.

Investors Business Daily

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 S&P 500 Stocks to Buy in 2025 With Big Rebound Potential

As markets rise, a handful of resilient stocks that were bruised could rebound over 30%, powered by strong fundamentals and bullish prospects.

3 Nasdaq-100 Stocks With 25% to 53% Upside Potential

These three Nasdaq-100 Stocks shine as prime opportunities as analysts forecast 25% to 53% upside potential.

Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Despite Regeneron Pharmaceuticals’ significant underperformance relative to Nasdaq recently, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Regeneron Pharmaceuticals Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).

inkl

Read news from The Economist, FT, and more,
with one subscription

Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA)

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom

Regeneron stock toppled Thursday after the biotech giant reported lighter-than-expected sales of its new eye disease drug.

Investors Business Daily

Here's What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report

Here's What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report

Regeneron Pharmaceuticals is expected to report its fiscal third-quarter earnings this month, and analysts project a single-digit profit plunge.

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent

Regeneron stock rose Friday after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.

Investors Business Daily

Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling

Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling

Tesla led the S&P 500 index on Monday, moving toward a buy point. Regeneron Pharmaceuticals tumbled on a surprise court ruling.

Investors Business Daily

Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea

Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea

Regeneron stock toppled Monday after a judge unexpectedly rejected a request that would have prevented Amgen from launching an Eylea copycat.

Investors Business Daily

Is Regeneron Pharmaceuticals Stock Outperforming the S&P 500?

Is Regeneron Pharmaceuticals Stock Outperforming the S&P 500?

Regeneron Pharmaceuticals has outperformed the broader S&P 500 Index over the past year, and Wall Street analysts remain bullish on the stock’s prospects.

Get all your
news in one place.

100’s of premium titles.
One news app.

Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts remain bullish on the stock’s prospects.

Investors Business Daily

Regeneron Pharma Tops Its Buy Zone Despite Mixed Sales For Blockbuster Eye Drug

Regeneron stock edged higher Thursday despite mixed results for its bread-and-butter eye-disease treatment franchise, Eylea.

Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report

Regeneron Pharmaceuticals is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit increase.

Investors Business Daily

Swing Trading Regeneron Stock Shows How To Bob And Weave

What do boxers and swing traders have in common? Avoiding big hits and striking at opportunities when they come. Here's how.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks

There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.

Investors Business Daily

Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club

Regeneron stock joined the 1,000-club this month as enthusiasm grows for its blockbuster drug, Dupixent, in COPD treatment.

How Is Regeneron Pharmaceuticals' Stock Performance Compared to Other Biotechnology Stocks?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts are optimistic about the stock’s outlook.

Investors Business Daily

Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms

Regeneron stock jumped early Thursday, bolstered by strong sales of a high-dose version of its blockbuster eye disease treatment, Eylea.

Regeneron To Defend Against DOJ Complaint On Drug Pricing

Regeneron faces DOJ legal challenge over drug-price manipulation allegations, vows to defend itself. Case could impact pharmaceutical industry and drug pri...

Investors Business Daily

Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?

Regeneron stock toppled Thursday after the DOJ filed a lawsuit saying the drugmaker fraudulently inflated the prices of its drug, Eylea.

US Appeals Court Revives Regeneron Antitrust Lawsuit Against Novartis

U.S. appeals court revives Regeneron's antitrust lawsuit against Novartis, highlighting alleged anticompetitive behavior.

People

Robert F. Kennedy Jr

Christopher Raymond

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

243,969 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play